The high price of new hepatitis C drugs is keeping them out of reach of many prison inmates, limiting the ability to cure the disease in one of the nation's largest infected populations. . Two treatments introduced late last year have steep price tags: Gilead Sciences Inc.'s Sovaldi has a list price of $84,000 per patient for a standard 12-week treatment, while Johnson & Johnson's Olysio costs $66,000 for the same duration. . ...
  